Dark Forest Capital Management LP Purchases 14,430 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Dark Forest Capital Management LP boosted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 112.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,314 shares of the company’s stock after acquiring an additional 14,430 shares during the period. Dark Forest Capital Management LP’s holdings in Sana Biotechnology were worth $149,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SANA. XTX Topco Ltd bought a new position in shares of Sana Biotechnology during the 2nd quarter valued at about $100,000. Hartline Investment Corp bought a new stake in Sana Biotechnology in the 1st quarter valued at approximately $136,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Sana Biotechnology by 20.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after acquiring an additional 5,090 shares during the last quarter. Arizona State Retirement System boosted its position in Sana Biotechnology by 36.7% during the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after acquiring an additional 9,940 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Sana Biotechnology by 14.8% during the 1st quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock worth $327,000 after acquiring an additional 4,210 shares in the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Stock Down 2.8 %

SANA opened at $4.16 on Tuesday. Sana Biotechnology, Inc. has a twelve month low of $2.74 and a twelve month high of $12.00. The company has a fifty day moving average of $5.13 and a 200-day moving average of $6.80. The stock has a market cap of $921.45 million, a PE ratio of -2.72 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.13 EPS for the current fiscal year.

Insider Activity

In related news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on SANA. HC Wainwright reduced their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, August 9th. Citigroup boosted their price target on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price target for the company.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.